<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36740547</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-7583</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Disability and health journal</Title><ISOAbbreviation>Disabil Health J</ISOAbbreviation></Journal><ArticleTitle>Post-COVID conditions and healthcare utilization among adults with and without disabilities-2021 Porter Novelli FallStyles survey.</ArticleTitle><Pagination><StartPage>101436</StartPage><MedlinePgn>101436</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dhjo.2022.101436</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1936-6574(22)00201-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Adults with disabilities are at increased risk for SARS-CoV-2 infection and severe disease; whether adults with disabilities are at an increased risk for ongoing symptoms after acute SARS-CoV-2 infection is unknown.</AbstractText><AbstractText Label="OBJECTIVES">To estimate the frequency and duration of long-term symptoms (&gt;4 weeks) and health care utilization among adults with and without disabilities who self-report positive or negative SARS-CoV-2 test results.</AbstractText><AbstractText Label="METHODS">Data from a nationwide survey of 4510 U.S. adults administered from September 24, 2021-October 7, 2021, were analyzed for 3251 (79%) participants who self-reported disability status, symptom(s), and SARS-CoV-2 test results (a positive test or only negative tests). Multivariable models were used to estimate the odds of having &#x2265;1 COVID-19-like symptom(s) lasting &gt;4 weeks by test result and disability status, weighted and adjusted for socio-demographics.</AbstractText><AbstractText Label="RESULTS">Respondents who tested positive for SARS-CoV-2 had higher odds of reporting &#x2265;1 long-term symptom (with disability: aOR&#xa0;=&#xa0;4.50 [95% CI: 2.37, 8.54] and without disability: aOR&#xa0;=&#xa0;9.88 [95% CI: 7.13, 13.71]) compared to respondents testing negative. Among respondents who tested positive, those with disabilities were not significantly more likely to experience long-term symptoms compared to respondents without disabilities (aOR&#xa0;=&#xa0;1.65 [95% CI: 0.78, 3.50]). Health care utilization for reported symptoms was higher among respondents with disabilities who tested positive (40%) than among respondents without disabilities who tested positive (18%).</AbstractText><AbstractText Label="CONCLUSIONS">Ongoing symptoms among adults with and without disabilities who also test positive for SARS-CoV-2 are common; however, the frequency of health care utilization for ongoing symptoms is two-fold among adults with disabilities.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Maureen J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>CDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Chronic Viral Diseases Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging Zoonotic and Infectious Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: yax6@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldstein</LastName><ForeName>Leora R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>CDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: nqw5@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holbrook</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Disability Science and Program Team, Division of Human Development and Disability, U.S. Centers for Disease Control and Prevention, National Center for Birth Defects and Developmental Disorders, 4770 Buford Hwy NE, Mailstop S106-4, Atlanta, GA, 30341-3717, USA. Electronic address: vzt4@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plumb</LastName><ForeName>Ian D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: ydk9@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Accorsi</LastName><ForeName>Emma K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Epidemic Intelligence Service, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: vgi0@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qing C</ForeName><Initials>QC</Initials><AffiliationInfo><Affiliation>Disability Science and Program Team, Division of Human Development and Disability, U.S. Centers for Disease Control and Prevention, National Center for Birth Defects and Developmental Disorders, 4770 Buford Hwy NE, Mailstop S106-4, Atlanta, GA, 30341-3717, USA. Electronic address: gso9@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Disability Science and Program Team, Division of Human Development and Disability, U.S. Centers for Disease Control and Prevention, National Center for Birth Defects and Developmental Disorders, 4770 Buford Hwy NE, Mailstop S106-4, Atlanta, GA, 30341-3717, USA. Electronic address: ycx6@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Jean Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>CDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Division of Reproductive Health, National Center for Chronic Diseases Prevention and Health Promotion, U.S. Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop S107-1, Atlanta, GA, 30341-3717, USA. Electronic address: fob1@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanga</LastName><ForeName>Valentine</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Child Development Studies Team, Division of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, U.S. Centers for Disease Control and Prevention, 4770 Buford Hwy S106-4, Atlanta, GA 30341-3717, USA; Epidemic Intelligence Service, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: qdy0@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konkle</LastName><ForeName>Stacey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Epidemic Intelligence Service, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: qdv8@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitrov</LastName><ForeName>Lina V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Child Development Studies Team, Division of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, U.S. Centers for Disease Control and Prevention, 4770 Buford Hwy S106-4, Atlanta, GA 30341-3717, USA; Oak Ridge Institute for Science and Education, U.S. Centers for Disease Control and Prevention Research Participation Programs, P.O. Box 117, Oak Ridge, TN, 37831-0117, USA. Electronic address: qwj7@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertolli</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Chronic Viral Diseases Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging Zoonotic and Infectious Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: jub7@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saydah</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: zle0@cdc.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Disabil Health J</MedlineTA><NlmUniqueID>101306633</NlmUniqueID><ISSNLinking>1876-7583</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006233" MajorTopicYN="Y">Disabled Persons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Disabilities</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID conditions</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of SARS-CoV-2 infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>5</Day><Hour>22</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36740547</ArticleId><ArticleId IdType="pmc">PMC9762038</ArticleId><ArticleId IdType="doi">10.1016/j.dhjo.2022.101436</ArticleId><ArticleId IdType="pii">S1936-6574(22)00201-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>C.D.C. Post-COVID Conditions: Information for Healthcare Providers. 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html Accessed from:</Citation></Reference><Reference><Citation>Hernandez-Romieu A.C., Carton T.W., Saydah S., et al. Prevalence of select new symptoms and conditions among persons aged younger than 20 Years and 20 Years or older at 31 to 150 days after testing positive or negative for SARS-CoV-2. JAMA Netw Open. 4 Feb 2022 2022;(2) doi: 10.1001/jamanetworkopen.2021.47053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.47053</ArticleId><ArticleId IdType="pmc">PMC8817203</ArticleId><ArticleId IdType="pubmed">35119459</ArticleId></ArticleIdList></Reference><Reference><Citation>Underlying C.D.C.  2022. Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals.https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html Accessed from:</Citation></Reference><Reference><Citation>Yuan Y., Thierry J.M., Bull-Otterson L., et al. COVID-19 cases and hospitalizations among medicare beneficiaries with and without disabilities &#x2014; United States, January 1, 2020&#x2212;November 20, 2021. MMWR Morb Mortal Wkly Rep. 17 Jun 2022;71(24):791&#x2013;796. doi: 10.15585/mmwr.mm7124a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7124a3</ArticleId><ArticleId IdType="pubmed">35709015</ArticleId></ArticleIdList></Reference><Reference><Citation>28 Oct 2022. C.D.C. Disability Impacts All of Us.https://www.cdc.gov/ncbddd/disabilityandhealth/infographic-disability-impacts-all.html Accessed from:</Citation></Reference><Reference><Citation>Turk M.A., Mitra M. COVID-19 and people with disability: social and economic impacts. Disability and Health Journal. 2022 doi: 10.1016/j.dhjo.2021.101184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dhjo.2021.101184</ArticleId><ArticleId IdType="pmc">PMC8436049</ArticleId><ArticleId IdType="pubmed">34531003</ArticleId></ArticleIdList></Reference><Reference><Citation>Okoro C.A., Strine T.W., McKnight-Eily L., Verlenden J., Hollis N.D. Indicators of poor mental health and stressors during the COVID-19 pandemic, by disability status: a cross-sectional analysis. Disability and Health Journal. 2021;14 doi: 10.1016/j.dhjo.2021.101110/1936-6574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dhjo.2021.101110/1936-6574</ArticleId><ArticleId IdType="pmc">PMC8436151</ArticleId><ArticleId IdType="pubmed">33962896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryerson A.B., Rice C.E., Hung M.C., et al. Disparities in COVID-19 vaccination status, intent, and perceived access for noninstitutionalized adults, by disability status &#x2014; National Immunization Survey adult COVID module, United States, May 30&#x2013;June 26, 2021. MMWR Morb Mortal Wkly Rep. 1 October 2021 2021;70(39):1365&#x2013;1371. doi: 10.15585/mmwr.mm7039a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7039a2</ArticleId><ArticleId IdType="pmc">PMC8486390</ArticleId><ArticleId IdType="pubmed">34591826</ArticleId></ArticleIdList></Reference><Reference><Citation>Khavjou O.A., Anderson W.L.H., Honeycutt A., et al. State-level health care expenditures associated with disability. Publ Health Rep. 2021;136(4):441&#x2013;450. doi: 10.1177/0033354920979807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0033354920979807</ArticleId><ArticleId IdType="pmc">PMC8203048</ArticleId><ArticleId IdType="pubmed">33673781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunsky Y., Durbin A., Balogh R., Lin E., Palma L., Plumptre L. COVID-19 positivity rates, hospitalizations and mortality of adults with and without intellectual and developmental disabilities in Ontario, Canada. Disability and Health Journal. 2022;15 doi: 10.1016/j.dhjo.2021.101174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dhjo.2021.101174</ArticleId><ArticleId IdType="pmc">PMC8312045</ArticleId><ArticleId IdType="pubmed">34340949</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott W., Tao S., Shea L. COVID-19 risk: adult Medicaid beneficiaries with autism, intellectual disability, and mental health conditions. Autism. 2021:1&#x2013;13. doi: 10.1177/1362361321103966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1362361321103966</ArticleId><ArticleId IdType="pmc">PMC8859009</ArticleId><ArticleId IdType="pubmed">34420427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebrasseur A., Fortin-Bedard N., Lettre J., et al. Impact of COVID-19 on people with physical disabilities: a rapid review. Disability and Health Journal. 2021;14 doi: 10.1016/j.dhjo.2020.101014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dhjo.2020.101014</ArticleId><ArticleId IdType="pmc">PMC7603994</ArticleId><ArticleId IdType="pubmed">33158795</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakespeare T., Ndagire F., Seketi Q.E. Triple jeopardy: disabled people and the COVID-19 pandemic. Lancet. 10 April 2021 2021;397:1331&#x2013;1333. doi: 10.1016/S0140-6736(21)00625-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00625-5</ArticleId><ArticleId IdType="pmc">PMC7963443</ArticleId><ArticleId IdType="pubmed">33740474</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown H.K., Saha S., Chan T.C.Y., et al. Outcomes in patients with and without disability admitted to hospital with COVID-19: a retrospective cohort study. CMAJ (Can Med Assoc J) 2022 January 31 2022;194:E112&#x2013;E121. doi: 10.1503/cmaj.211277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.211277</ArticleId><ArticleId IdType="pmc">PMC8900770</ArticleId><ArticleId IdType="pubmed">35101870</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter Novelli Styles  https://styles.porternovelli.com/consumer-youthstyles/</Citation></Reference><Reference><Citation>Ipsos KnowledgePanel Accessed 21 April 2022. 2022. https://www.ipsos.com/en-us/solutions/public-affairs/knowledgepanel?msclkid=bc1672f5c1ae11eca70492b1450649d6</Citation></Reference><Reference><Citation>U.S. Census Bureau  . 2020. American Community Survey (ACS) March 2020 Annual Social and Economic Supplement, S1810: Disability Characteristics.https://data.census.gov/cedsci/all?q=disability [dataset] Accessed from.</Citation></Reference><Reference><Citation>U.S. Census Bureau  . 2020. Current Population Survey (CPS) Datasets.https://www.census.gov/data/datasets/time-series/demo/cps/cps-asec.2020.html#list-tab-S0DSGKHMB58P2A9KF5 [dataset] Accessed from:</Citation></Reference><Reference><Citation>16 Sept 2020. C.D.C. Disability and Health Overview.https://www.cdc.gov/ncbddd/disabilityandhealth/disability.html Accessed from:</Citation></Reference><Reference><Citation>2022. U.S. Census Bureau.How disability data are collected from the American community survey.https://www.census.gov/topics/health/disability/guidance/data-collection-acs.html Accessed from:</Citation></Reference><Reference><Citation>Wanga V., Chevinsky J.R., Dimitrov L.V., et al. Long-term symptoms among adults tested for SARS-CoV-2 &#x2014; United States, January 2020&#x2212;April 2021. MMWR Morb Wkly Rep. 2021;70(36) doi: 10.15585/mmwr.mm7036a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7036a1</ArticleId><ArticleId IdType="pmc">PMC8437054</ArticleId><ArticleId IdType="pubmed">34499626</ArticleId></ArticleIdList></Reference><Reference><Citation>C.D.C  Archived COVID-19 Vaccination Schedules. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/archived-covid-19-vacc-schedule.html</Citation></Reference><Reference><Citation>Mbaeyi S., Oliver S.E., Collins J.P., et al. The Advisory Committee on Immunization Practices&#x2019; Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines &#x2014; United States, 2021. MMWR Morb Mortal Wkly Rep. 5 Nov 2021 2021;70:1545&#x2013;1552. doi: 10.15585/mmwr.mm7044e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7044e2</ArticleId><ArticleId IdType="pmc">PMC8568093</ArticleId><ArticleId IdType="pubmed">34735422</ArticleId></ArticleIdList></Reference><Reference><Citation>15 October 2021. C.D.C. When You&#x2019;ve Been Fully Vaccinated: How to Protect Yourself and Others.https://public4.pagefreezer.com/browse/CDC%20Covid%20Pages/11-05-2022T12:30/https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated_archived.html [Accessed 1 June 2022]</Citation></Reference><Reference><Citation>Konkle S.L., Magleby R., Segaloff H., et al. Post-COVID Condition Symptom Clusters and Associations with Return to Pre-COVID Health &#x2014; Results from a 2021 Multi-State Survey. CDC Epidemic Intelligence Service 2022 Annual Conference, Atlanta, GA, USA. 2-5 May, 2022. (oral presentation)</Citation></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw Open. 13 Oct 2021 2021;4(10) doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med (New York, NY, U S) April 2021 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Saydah S.H., Brooks J.T., Jackson B.R. Surveillance for post-COVID conditions is necessary: addressing the challenges with multiple approaches. J&#xa0;Gen Intern Med. 2022 doi: 10.1007/s11606-022-07446-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07446-z</ArticleId><ArticleId IdType="pmc">PMC8853042</ArticleId><ArticleId IdType="pubmed">35167066</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Malden D.E., Liu I.A., al e. Health care utilization in the 6 Months following SARS-CoV-2 infection. JAMA Netw Open. 2022;5(8) doi: 10.1001/jamanetworkopen.2022.25657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.25657</ArticleId><ArticleId IdType="pmc">PMC9375168</ArticleId><ArticleId IdType="pubmed">35960522</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund E.M., Ayers K.B. Ever-changing but always constant: "Waves" of disability discrimination during the COVID-19 pandemic in the United States. Disabil Health J. 2022;15(4) doi: 10.1016/j.dhjo.2022.101374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dhjo.2022.101374</ArticleId><ArticleId IdType="pmc">PMC9436863</ArticleId><ArticleId IdType="pubmed">36156274</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings G.H., Beail N. Long-COVID in people with intellectual disabilities: a call for research of a neglected area. Br J Learn Disabil. 2022 doi: 10.1111/bld.12499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bld.12499</ArticleId><ArticleId IdType="pmc">PMC9538317</ArticleId><ArticleId IdType="pubmed">36247098</ArticleId></ArticleIdList></Reference><Reference><Citation>Korves C., Izurieta H.S., Smith J., et al. Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: self-controlled risk interval analysis. Vaccine. 2022;S0264&#x2013;410X(22):816&#x2013;817. doi: 10.1016/j.vaccine.2022.06.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.047</ArticleId><ArticleId IdType="pmc">PMC9212417</ArticleId><ArticleId IdType="pubmed">35773122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>